A Genetic Folding Strategy Based Support Vector Machine to Optimize Lung Cancer Classification.

Front Artif Intell

Department of Business and Data Analytics, University of Huddersfield, Huddersfield, United Kingdom.

Published: June 2022

Cancer is defined as an abnormal growth of human cells classified into benign and malignant. The site makes further classification of cancers of initiation and genomic underpinnings. Lung cancer displays extreme heterogeneity, making genomic classification vital for future targeted therapies. Especially considering lung cancers account for 1.76 million deaths worldwide annually. However, tumors do not always correlate to cancer as they can be benign, severely dysplastic (pre-cancerous), or malignant (cancerous). Lung cancer presents with ambiguous symptoms, thus is difficult to diagnose and is detected later compared to other cancers. Diagnosis relies heavily on radiology and invasive procedures. Different models developed employing Artificial Intelligence (AI), and Machine Learning (ML) have been used to classify various cancers. In this study, the authors propose a Genetic Folding Strategy (GFS) based model to predict lung cancer from a lung cancer dataset. We developed and implemented GF to improve Support Vector Machines (SVM) classification kernel functions and used it to classify lung cancer. We developed and implemented GF to improve SVM classification kernel functions and used it to classify lung cancer. Classification performance evaluations and comparisons between the authors' GFS model and three SVM kernels, linear, polynomial and radial basis function, were conducted thoroughly on real lung cancer datasets. While using GFS in classifying lung cancer, the authors obtained an accuracy of 96.2%. This is the highest current accuracy compared to other kernels.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280892PMC
http://dx.doi.org/10.3389/frai.2022.826374DOI Listing

Publication Analysis

Top Keywords

lung cancer
36
cancer
11
lung
10
genetic folding
8
folding strategy
8
support vector
8
cancer classification
8
developed implemented
8
implemented improve
8
svm classification
8

Similar Publications

Co-blocking TIGIT and PVRIG using a novel bispecific antibody enhances anti-tumor immunity.

Mol Cancer Ther

January 2025

Jiangsu Hengrui Pharmaceutical Co. Ltd, Shanghai, China.

TIGIT and PVRIG are immune checkpoints co-expressed on activated T and NK cells, contributing to tumor immune evasion. Simultaneous blockade of these pathways may enhance therapeutic efficacy, positioning them as promising dual targets for cancer immunotherapy. This study aimed to develop a bispecific antibody (BsAb) to co-target TIGIT and PVRIG.

View Article and Find Full Text PDF

Objectives: Despite the widely recognised high mortality rate among patients with hip fracture, the variation in death rates by gender and cause has been less explored. This study aimed to investigate mortality rates and causes of death in patients who underwent hip fracture surgery, and to compare them with those of the general population. A secondary objective was to compare the results of Internal Fixation versus Arthroplasty in these patients.

View Article and Find Full Text PDF

Background: Dysbiosis of the lung microbiome can contribute to the initiation and progression of lung cancer. Synchronous multiple primary lung cancer (sMPLC) is an increasingly recognized subtype of lung cancer characterized by high morbidity, difficulties in early detection, poor prognosis, and substantial clinical challenges. However, the relationship between sMPLC pathogenesis and changes in the lung microbiome remains unclear.

View Article and Find Full Text PDF

Subtype-specific human endogenous retrovirus K102 envelope protein is a novel serum immunosuppressive biomarker of cancer.

Front Immunol

January 2025

Department of Hematology and Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Immune dysfunction is one of the hallmarks of cancer and plays critical roles in immunotherapy resistance, but there is no serum biomarker that can be used to evaluate immune-dysfunction status of cancer patients. Here, we identified subtype-specific human endogenous retrovirus K102 envelope (HERV-K102-Env) with immunosuppressive activity in circulating blood as a novel serum immunosuppressive biomarker of cancer. We first generated monoclonal antibodies against K102-Env with high sensitivity and specificity, and we developed an ELISA assay to detect serum K102-Env.

View Article and Find Full Text PDF

Background: Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) exhibit a notably aggressive phenotype, which is associated with poor patient survival outcomes. These tumors are generally resistant to conventional cytotoxic chemotherapy, thereby limiting the availability of effective treatment options.

Case Presentation: We describe a 69-year-old AIDS patient who initially presented with a fused, enlarged lymph node on the right clavicle and mild, unexplained pain under the right axilla that worsened with severe coughing episodes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!